ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
38.16
-0.18%
US Tech 100
19,436.00
-0.73%
S&P 500
5,738.17
-0.13%
US Dollar vs CAD
1.35235
0.00%
Bitcoin
65,525.80
-0.53%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Carisma Therapeutics Inc (CARM) Share Price

Carisma Therapeutics Inc

Carisma Therapeutics Inc (CARM)

Carmanah Minerals Corp
Carrefour Property Development
1.01
0.0224
(2.27%)
Closed September 29 3:00PM
Delayed by 15 minutes
1.01
0.00
(0.00%)
After Hours: 5:56PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
1.01
Bid
0.98
Ask
1.59
Volume
106,378
0.9791 Day's Range 1.03
0.80 52 Week Range 4.86
Market Cap
41.96M
Previous Close
0.9876
Open
0.9791
Last Trade
1
@
1.02
Last Trade Time
Financial Volume
US$ 107,592
VWAP
1.0114
Average Volume (3m)
233,440
Shares Outstanding
41,544,975
Dividend Yield
-
PE Ratio
-0.48
Earnings Per Share (EPS)
-2.09
Revenue
14.92M
Net Profit
-86.88M

About Carisma Therapeutics Inc

Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company¿s macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell t... Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company¿s macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company¿s lead product candidate, CT-0508, is a Chimeric Antigen Receptor Macrophage (CAR-M) to be evaluated in a human clinical trial and is intended to treat solid tumors that overexpress HER2. The Company¿s second product candidate, CT-0525, is also intended to treat solid tumors that overexpress HER2, is in preclinical development. Beyond CT-0508 and CT-0525, the Company has a pipeline of cell therapy assets in various stages of pre-clinical development. The Company is also developing in vivo CAR-M gene therapies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.carismatx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Carisma Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CARM. The last closing price for Carisma Therapeutics was US$0.99. Over the last year, Carisma Therapeutics shares have traded in a share price range of US$ 0.80 to US$ 4.86.

Carisma Therapeutics currently has 41,544,975 shares outstanding. The market capitalization of Carisma Therapeutics is US$41.03 million. Carisma Therapeutics has a price to earnings ratio (PE ratio) of -0.48.

Ask ADVFN Intelligence (AI)

CARM Latest News

More News

CARMILA : COMMUNIQUÉ DE PRESSE EN DATE DU 25 SEPTEMBRE 2024

OFFRE PUBLIQUE D’ACHAT SIMPLIFIÉE VISANT LES ACTIONS DE LA SOCIÉTÉ GALIMMO SCA SUIVIE D’UN RETRAIT OBLIGATOIRE Initiée par la société Carmila Regulatory News: Carmila (Paris:CARM) : Ne pas...

September 25 2024
Business Wire

CARMILA : COMMUNIQUÉ DE PRESSE EN DATE DU 24 SEPTEMBRE 2024

OFFRE PUBLIQUE D’ACHAT SIMPLIFIÉE VISANT LES ACTIONS DE LA SOCIÉTÉ GALIMMO SCA SUIVIE D’UN RETRAIT OBLIGATOIRE Initiée par la société Carmila  Regulatory News: Carmila (Paris:CARM) : MISE À...

September 24 2024
Business Wire

Successful Completion of Tender Offer on Carmila’s Bonds With €200,100,000 of Bonds Tendered

Regulatory News: Carmila (Paris:CARM) successfully completed its tender offer, announced on 16 September 2024, on the following series of existing notes: €300,000,000 1.625 per cent. Notes due...

September 24 2024
Business Wire

Carmila Successfully Issues Inaugural €300M 7-Year Green Bond, Paying a Fixed Annual Coupon of 3.875%

Regulatory News: Carmila (Paris:CARM) today issued its first green bond for a total amount of €300 million. With a maturity of just over seven years, the bonds fall due on 25 January 2032 and...

September 17 2024
Business Wire

Carmila Announces the Launch of a Tender Offer on Its Existing Notes Maturing in May 2027, March 2028, October 2028 and April 2029, and Announces Its Intention to Issue New Notes

Regulatory News: Carmila (Paris:CARM) announces today the launch of a tender offer on the following series of existing notes: €300,000,000 1.625 per cent. Notes due 30 May 2027 (ISIN...

September 16 2024
Business Wire

Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases

Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases PR Newswire PHILADELPHIA, Sept. 10, 2024 Building on successful pre-clinical in vivo CAR-M...

September 10 2024
PR Newswire (US)

Carmila : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiers

Regulatory News: Carmila (Paris:CARM) : Date Nombre d’actions composant le capital social Nombre réel de droits de vote (déduction faite des actions auto- détenues) Nombre théorique de droits de...

September 09 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.033.06122448980.981.020.93171241750.97651917CS
4-0.09-8.181818181821.11.13730.91431474700.99197051CS
12-0.32-24.06015037591.331.380.82334401.08677387CS
26-1.28-55.89519650662.292.3850.82856121.3294235CS
52-3.25-76.29107981224.264.860.82346251.92478651CS
156-4.78-82.55613126085.799.76620.82407303.52759052CS
260-4.78-82.55613126085.799.76620.82407303.52759052CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
UXINUxin Ltd
US$ 5.145
(81.80%)
46.69M
ONCOOnconetix Inc
US$ 5.92
(76.43%)
34.68M
JFU9F Inc
US$ 2.3101
(76.34%)
2.48M
NANano Labs Ltd
US$ 1.005
(73.31%)
3.34M
CNEYCN Energy Group Inc
US$ 0.9473
(63.36%)
221.89M
ICGIntchains Group Ltd
US$ 4.77
(-43.75%)
2.86M
EDBLEdible Garden AG Inc
US$ 0.288
(-38.09%)
5.79M
DSYBig Tree Cloud Holdings Limited
US$ 2.44
(-28.24%)
416.35k
NVNOenVVeno Medical Corporation
US$ 3.255
(-27.67%)
2.36M
ADTXAditxt Inc
US$ 0.165
(-24.83%)
12.23M
NVDANVIDIA Corporation
US$ 121.40
(-2.13%)
271.06M
XPONExpion360 Inc
US$ 0.0717
(11.34%)
266.01M
CNEYCN Energy Group Inc
US$ 0.9473
(63.36%)
221.89M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.1462
(7.03%)
207.04M
SQQQProShares UltraPro Short QQQ
US$ 7.45
(1.78%)
133.67M

CARM Discussion

View Posts
PonkenPlonken PonkenPlonken 6 days ago
I appreciate you reaching out. I like to follow the money in bioland or predict where it might go. Hence i really like this. Their CAR M CD47 approach is not new and many wished for these trials. The risk however is huge hence no one bit this (monotherapy trial with safety as primary endpoint is almost random)

I am having a very close eye on this as they will share the first clinical data in q4. Any price increase prior might hint at things being right/a rally coming. The problem is, this is monotherapy only and not the one where they combine with the mRNA tech (which is likely where the good stuff is)

So down the road we will be getting some great hints here on whether this might be "THE next big thing" or not.... A LOT of targets nominated by them...
👍️0
jondoeuk jondoeuk 1 week ago
From this: “Without a doubt there's big biological risk here,” says Carisma CSO Michael Klichinsky. Researchers have yet to prove either the efficacy or the approvability of CAR macrophages. But solid tumours account for 90% of the cancer burden, making the possibility of activity in these settings with an in vivo reprogramming agent all the more appealing. “We’re going after a real unmet need,” he adds. https://www.nature.com/articles/d41573-024-00150-z
👍️0
Prestotic Prestotic 1 month ago
Vdog, your dog stock shedding another 8.33% today on a pathetic 2 million shares. Going to trips withou a contract soon. Hope you get this message. You could be in Carisma if only you listened.
👍️0
Prestotic Prestotic 1 month ago
Vdog has no Carisma Therapeutics. Losers like him love losers like VXIT. Carisma up 50 % in 2 weeks, Vxit down 50%. LOVE to say I TOLD YOU SO! How's your DD treating you JA
👍️0
Prestotic Prestotic 1 month ago
Eat shi* vdog
👍️0
Prestotic Prestotic 1 month ago
Another 50,000 getting accumulated/ covered @ $1.04. To the moon, soon.
👍️0
Prestotic Prestotic 1 month ago
No noise here because Carisma is not a penny stock. This has moved nicely off of the bottom of .80 from last week. Plus 20%. Positive results from phase 2 study will solidify deal with Moderna and get this back up to levels seen mid June. Today's action, including buy, buy, buy of 75000 shares at 3:30 pm shows accumulation, or at least some worried shorts covering. Looking for strong move up on phase 2 results.
👍️0
Prestotic Prestotic 1 month ago
No noise here because Carisma in not a penny stock. This has moved nicely off of the bottom of .80 from last week. Plus 20%. Positive results from phase 2 study will solidify deal with Moderna and get this back up to levels seen mid July. Today's action, including buy, buy, buy of 75000 shares around 2pm shows accumulation, or at least something worried shorts covering. Looking for strong move up on phase 2 results.
👍️0
CancunCharlie CancunCharlie 2 months ago
Is there anyone here?? No comments in over a month. I think this looks good, but I'm wondering why it's so quite here.
👍️0
PonkenPlonken PonkenPlonken 3 months ago
pretty strong
nice tech$
👍️0
glenn1919 glenn1919 3 months ago
CARM.......................https://stockcharts.com/h-sc/ui?s=CARM&p=W&b=5&g=0&id=p86431144783
👍️0
Awl416 Awl416 3 months ago
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
👍️0
Termite7 Termite7 4 months ago
Could it be CARM under $0.30 ....???.......Thanks!!!
👍️0
axelvento axelvento 4 months ago
$1.46 bouncer
👍️0
PonkenPlonken PonkenPlonken 5 months ago
https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-023-00537-x
MRNA provides the tech, 3bln + in biobucks and has not so distant private relative with TOP tier c suite.
👍️0
Monksdream Monksdream 6 months ago
CARM under $3
👍️0
mrplmer mrplmer 9 months ago
Whatever happened with their acquisition of Sesn Bio and their Bladder Cancer
👍️0
mrplmer mrplmer 9 months ago
Whatever happened with their acquisition of Sesn Bio and their Bladder Cancer
👍️0
81vette 81vette 10 months ago
1st higher high today and bid growing now,I got some 2.64,will see if dump continues or not
👍️0
81vette 81vette 10 months ago
Yea,distribution only so far today,I am watching for accumulation to start after this dumpathon,short interest went up 300% today also, 100k now,no sign of institutional buying yet,they currently hold 19%
👍️0
stock1ace1 stock1ace1 10 months ago
Red on news .. we no what that means lol
👍️0
81vette 81vette 10 months ago
Deal with Moderna for cancer cures,institutional might buy now lol,went up last time on this news,analysts target $9.50,short 2.45M,not optionable is good,gap filled down now,52 week low 2 weeks ago
👍️0

Your Recent History

NASDAQ
CARM
Carisma Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved